Proliferation against survivin loaded DCs was minimal for both myeloma patients and healthy donors at three days indicating that myeloma patients do not simply harbor primed survivin specific T effectors with different proliferation kinetics. This evidence concerns the gene BIRC5 and plasma cell myeloma.